Share This Page
Drug Sales Trends for STRATTERA
✉ Email this page to a colleague
Annual Sales Revenues and Units Sold for STRATTERA
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| STRATTERA | ⤷ Subscribe | ⤷ Subscribe | 2021 |
| STRATTERA | ⤷ Subscribe | ⤷ Subscribe | 2020 |
| STRATTERA | ⤷ Subscribe | ⤷ Subscribe | 2019 |
| STRATTERA | ⤷ Subscribe | ⤷ Subscribe | 2018 |
| STRATTERA | ⤷ Subscribe | ⤷ Subscribe | 2017 |
| STRATTERA | ⤷ Subscribe | ⤷ Subscribe | 2016 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
STRATTERA Market Analysis and Financial Projection
Market Analysis and Sales Projections for Strattera
Introduction to Strattera
Strattera, known generically as atomoxetine, is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). It was first approved by the FDA in 2002 and has been a significant player in the ADHD treatment market, particularly as a non-stimulant alternative.
Historical Sales Performance
Strattera has been a substantial earner for Eli Lilly, the pharmaceutical company that developed and marketed the drug. In its peak, Strattera generated significant revenue, with sales reaching $535 million annually in the U.S. and $854 million globally in 2016[4][5].
Impact of Patent Expiration
A critical turning point for Strattera came in 2017 when its patent expired. Following this, the FDA approved the first generic versions of atomoxetine from several manufacturers, including Apotex, Teva Pharmaceuticals, Aurobindo Pharma, and Glenmark Pharmaceuticals. This led to a dramatic shift in the market dynamics for Strattera[4][5].
Generic Competition and Sales Decline
The introduction of generic versions of atomoxetine had a profound impact on Strattera's sales. With multiple generic competitors entering the market, Strattera's sales plummeted. Estimates suggested that Strattera's U.S. sales would drop from $535 million annually to just $13 million by 2022[4][5].
Current Market Status
As of November 2023, Eli Lilly has discontinued all strengths of Strattera from the marketplace, and the generic version, atomoxetine, is now the primary option available for patients. This transition has significantly reduced treatment costs for ADHD patients, with generic versions typically priced 80 to 85 percent lower than the branded version[5].
Market Trends and Growth in ADHD Treatment
Despite the decline in Strattera's sales, the overall ADHD treatment market continues to grow. The global ADHD market size was estimated at USD 14.3 billion in 2023 and is projected to grow at a CAGR of 3.7% from 2024 to 2030. This growth is driven by increasing awareness of ADHD, rising global prevalence, and escalating healthcare expenditure[3].
Role of Non-Stimulant Treatments
Non-stimulant treatments like Strattera (atomoxetine) play a crucial role in the ADHD market. The market is expected to reach USD 13.6 billion by 2034, with advancements in non-stimulant treatments driving this growth. Research into genetic and neurobiological aspects of ADHD is also stimulating the development of targeted therapies, further fueling the market[1].
Challenges Faced by Eli Lilly
Eli Lilly faced significant challenges following the patent expiration of Strattera. The company had to adjust its revenue forecasts and implement cost-cutting measures, including reducing its workforce and marketing expenses. Despite these challenges, Eli Lilly has continued to focus on other product lines and research initiatives to maintain its market position[2][4].
Consumer Impact
The availability of generic atomoxetine has been a boon for consumers, particularly those who rely on this medication for ADHD treatment. The significant reduction in treatment costs has made the medication more accessible, aligning with the FDA's priority of bringing generics to market to provide patients with more affordable treatment options[5].
Regulatory Considerations
Generic versions of atomoxetine, like the branded version, come with a "black box warning" regarding the increased risk of suicidal thoughts, particularly in teenagers and young adults. The FDA's approval process ensures that these generics meet rigorous standards, providing patients with safe and effective treatment alternatives[5].
Key Takeaways
- Sales Decline: Strattera's sales have significantly declined since the introduction of generic versions, dropping from $535 million to $13 million annually.
- Generic Availability: The generic version of atomoxetine is now the primary treatment option, offering significant cost savings for patients.
- Market Growth: The overall ADHD treatment market continues to grow, driven by increasing awareness and healthcare expenditure.
- Non-Stimulant Treatments: Advancements in non-stimulant treatments are driving market growth, with Strattera (atomoxetine) playing a historical role in this segment.
- Consumer Benefits: The availability of generic atomoxetine has made ADHD treatment more affordable and accessible.
Frequently Asked Questions
Q: What is Strattera, and how is it used? A: Strattera, known generically as atomoxetine, is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD).
Q: What happened to Strattera's sales after its patent expired? A: Following the patent expiration in 2017, Strattera's sales plummeted due to the introduction of generic versions, dropping from $535 million to $13 million annually.
Q: Who are the manufacturers of the generic versions of Strattera? A: The generic versions of atomoxetine are manufactured by companies such as Apotex, Teva Pharmaceuticals, Aurobindo Pharma, and Glenmark Pharmaceuticals.
Q: How has the availability of generic atomoxetine impacted consumers? A: The availability of generic atomoxetine has significantly reduced treatment costs for ADHD patients, making the medication more accessible and affordable.
Q: What is the current market status of Strattera? A: As of November 2023, Eli Lilly has discontinued all strengths of Strattera, and the generic version, atomoxetine, is now the primary treatment option available.
Sources:
- Biospace - Attention Deficit Hyperactivity Disorder Market Size to Reach USD 13.6 Billion by 2034[1]
- PharmaTimes - Lilly cuts sales forecast as Strattera patent is declared invalid[2]
- Grand View Research - Attention Deficit Hyperactivity Disorder Market Report, 2030[3]
- FiercePharma - Strattera, Lilly's now-off-patent ADHD med, expected to be trampled by generics[4]
- ADDitude - FDA Approves First Generic Versions of Strattera[5]
More… ↓
